Tumor Necrosis Factor–Alpha Gene Expression in Human Whole Blood

Abstract

Tumor necrosis factor‐alpha (TNF) is recognized as a principal mediator of a variety of pathophysiologic and immunologic events. Lipopolysaccharide (LPS) challenge, either in vitro or in vivo, results in significant TNF production. In this study we present data demonstrating LPS‐induced TNF mRNA expression and bioactivity using an in vitro tissue system of whole blood (WB). The kinetics of LPS‐induced TNF production by WB was significantly accelerated as compared to isolated cultured peripheral blood monocytes (PBM). At post‐LPS challenge, plasma from WB demonstrated a rapid rise in TNF bioactivity, peaking by 4 hr (1,021 units/ml/106 cells), plateauing between 4 and 8 hr, and then decreasing over the next 16 hr. In contrast, the highest measured TNF bioactivity from PBM did not occur until the 24‐hr time‐point (175 units/ml/106 cells). Whole blood buffy‐coat TNF mRNA was assessed by Northern blot analysis, and demonstrated significant TNF mRNA accumulation at 1 hr and a peak 2 hr post‐LPS challenge. By 8 hr TNF mRNA was undetectable. Concomitant administration of LPS with either prostaglandin E2 (10‐6M) or Dexamethasone (10‐6M) resulted in significant suppression of LPS‐induced TNF production. This data supports WB as a useful in vitro medium for the molecular and cellular analyis of TNF. As specialized connective tissue, WB may provide an important environment to study the pharmacologic manipulation of TNF mRNA and bioactivity.